Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Moderna

AI is already changing the corporate org chart

AI isn't just a new tool for the modern workplace; it's quietly reshaping how companies are organized.

Fortune

Doctors decry RFK Jr decision to slash mRNA vaccine grants: ‘Our nation will pay in lives’

‘A tremendous step backward, the politicization of science, and RFK Jr., who has been a lifelong anti-vaccine propagandist and science denialist, is now making policy,’ one doctor said

The Independent UK

Despite RFK’s funding block, mRNA vaccines are too impressive to ignore

Scientists fear decision may increase vaccine hesitancy, but other countries are still willing to invest in research

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

RFK Jr. Halts $500 Million In mRNA Vaccine Projects Backed By Pfizer, Moderna: 'We're Prioritizing Safer, Broader Strategies'

The Department of Health and Human Services will cancel 22 vaccine development projects totaling $500 million, marking a major policy shift under Secretary Robert F. Kennedy Jr. that directly affects pharmaceutical giants like Pfizer Inc. (NYSE:PFE) and Moderna Inc. (NASDAQ:MRNA).

Benzinga

Moderna Stock: Is Wall Street Bullish or Bearish?

As Moderna has significantly lagged behind the broader market over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects.

Barchart

Novavax Stock Dips As Moderna's Woes Weigh On Vaccine Sector

Shares of Novavax Inc (NASDAQ:NVAX) are trading lower Friday morning, appearing to be caught in a downdraft affecting COVID-19 vaccine makers after rival Moderna Inc (NASDAQ:MRNA) reported disappointing second-quarter financial results and cut its full-year forecast.

Benzinga

Moderna's Key Patent Win Overshadowed By Gloomy Outlook

Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss, an improvement from a loss of $3.33 a year ago.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Moderna Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Moderna, Inc. (NASDAQ:MRNA) will release earnings results for the second quarter, before the opening bell on Friday, Aug. 1.

Benzinga

Moderna Announces 10% Workforce Cut Amid Declining COVID-19 Vaccine Sales, Regulatory Hurdles

Moderna Inc. (NASDAQ:MRNA) has announced plans to reduce its global workforce by approximately 10% by the end of the year due to decreasing COVID-19 vaccine sales and market uncertainty.

Benzinga

1 Analyst Thinks This Former Pandemic Winner Could Surge 500% This Year

This risky biotech company faces significant challenges ahead. But it has already proven its worth and may be able to do so again.

Barchart

What's Going On With Moderna Stock Wednesday?

Moderna Inc.’s (NASDAQ:MRNA) stock has surged approximately 37% in the last month but has dipped around 15% year to date.

Benzinga

What to Expect From Moderna's Next Quarterly Earnings Report

Moderna is expected to announce its second-quarter results in the upcoming month, and analysts expect a slight reduction in its losses.

Barchart

‘Tremendous uncertainty’ for cancer research as US officials target mRNA vaccines

Amid Trump cuts and state-level backlash, experts worry that progress in messenger RNA vaccines could stall

The Guardian - US

FDA Grants Complete Approval To Moderna's COVID-19 Vaccine For Children As Young As 6 Months

The U.S. Food and Drug Administration (FDA) has approved Moderna Inc.’s (NASDAQ:MRNA) supplemental Biologics License Application (sBLA) for Spikevax, the company’s COVID-19 vaccine, in children six months through 11 years of age who are at increased risk for COVID-19 disease.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

The Next Moderna? This Clinical-Stage Biotech Has Breakout Potential.

This clinical-stage biotech stock has a strong pipeline capable of creating the next Moderna.

The Independent UK

FDA vaccine official restricted COVID vaccine approvals against the advice of agency staff

A top official at the Food and Drug Administration recently overruled government scientists on the availability of two COVID-19 vaccines

The Independent UK

RFK Jr.'s made promises about vaccines. Here's what he's done as health secretary

The Department of Health and Human Services under Robert F

International Business Times UK

COVID Vaccine Side Effects: FDA Announces Rare Heart-Related Reactions - What You Should Know

FDA has updated safety warnings for the Pfizer-BioNTech (Comirnaty) and Moderna (Spikevax) COVID-19 vaccines.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

RFK Jr. Overhauls CDC Vaccine Panel, Sparking Expert Backlash, Boycott From Top Medical Group

Health Secretary Robert F. Kennedy Jr.'s newly reconstituted vaccine advisory panel is facing criticism from medical experts and former federal officials after its first meeting strayed sharply from established scientific review norms.

The Guardian - US

US experts fear all vaccines at risk as Trump officials target mRNA jabs

Administration’s actions signal move away from technology as health agencies see vaccine-related shakeups

Barchart

How Is Moderna’s Stock Performance Compared to Other Biotechnology Stocks?

Moderna has significantly underperformed other biotechnology stocks over the past year, and analysts remain cautious on the stock’s prospects.

Fortune

What you need to know about Moderna's new COVID vaccine, just approved by the FDA

The shot had previously been approved for everyone 12 and older. Now, there are limits.

The Independent UK

FDA approves Moderna's new lower-dose COVID-19 vaccine

The Food and Drug administration has approved a new COVID-19 vaccine made by Moderna but with limits on who can use it

The Independent UK

HHS cancels funding for bird flu vaccine development because of RNA concerns

The Trump administration said the move signals a ‘shift in federal vaccine funding priorities’

International Business Times

Moderna Loses $700M US Contract for Bird Flu Vaccine Development

Moderna loses $700 million U.S. contract to develop bird flu vaccine after government review ends funding.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Health and Human Services

the Food and Drug Administration

196 stories

the Department of Health and Human Services

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.